(+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate | 342603-65-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate
• 英文别名: tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate；N-methyl-N-methoxy-2-[(N-tert-butoxycarbonyl)amino]propanamide；tert-butyl 1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate；tert-butyl 1-(N-methoxy-N-methylcarbamoyl)ethylcarbamate；tert-butyl-1-(N-methoxy-N-methylcarbamoyl)ethylcarbamate；N2-(tert-butoxycarbonyl)-N-methoxy-N-methylalaninamide；tert-Butyl 2-(methoxy(methyl)amino)-1-methyl-2-oxoethylcarbamate；tert-butyl N-[1-[methoxy(methyl)amino]-1-oxopropan-2-yl]carbamate
• CAS: 342603-65-0
• 化学式: C₁₀H₂₀N₂O₄
• mdl: MFCD11977209
• 分子量: 232.28
• InChiKey: PWQIGBOSLQHOBT-UHFFFAOYSA-N

物化性质

• 熔点：
  150-151 °C
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate 在 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 26.0h， 生成 tert-butyl-3-hydroxy-2-methyl-1-oxo-1-phenylpropan-2-ylcarbamate
  参考文献：
  名称：

  A New Family of Small Molecules To Probe the Reactivation of Mutant p53

  摘要：

  Cells that express mutant p53 derived from cancers are selectively killed by a new class of small organic molecules. The protein p53 is recognized as one of the most important guardians in the body that prevents tumor development. Mutant forms of p53 are present in approximately 50% of all human cancers. Molecules that selectively kill cells expressing mutant p53 could become important chemotherapeutic agents. Our research focuses on developing a synthetically accessible class of molecules that can be easily modified to examine structural activity relationships and mechanism of biological activity or to optimize for anticancer activity. In this communication, a new class of molecules that selectively arrests growth of cells expressing two forms of mutant p53 is described. Synthetic routes to these compounds are also presented.

  DOI：

  10.1021/ja045752y
• 作为产物：
  描述：

  N-叔丁氧羰基-L-丙氨酸 、 二甲羟胺盐酸盐 生成 (+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate
  参考文献：
  名称：

  [EN] CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
  [FR] CERTAINES ENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS

  摘要：

  本文描述了调节PI3激酶活性的化学实体、含有这些化学实体的制药组合物以及使用这些化学实体治疗与PO激酶活性相关的疾病和病症的方法。

  公开号：

  WO2011008302A1
• 作为试剂：
  描述：

  2-氯-6-甲基-N-苯基苯甲酰胺 、 (+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate 在 (+/-)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate 作用下， 生成 tert-butyl N-[3-[[(1S)-1-(8-chloro-1-oxo-2-phenylisoquinolin-3-yl)ethyl]carbamoyl]pyrazolo[1,5-a]pyrimidin-2-yl]carbamate
  参考文献：
  名称：

  ACS Med. Chem. Lett. 2016, 7, 862-867

  摘要：

  DOI：

文献信息

• [EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES
  申请人：VPS 3 INC

  公开号：WO2018165520A1

  公开（公告）日：2018-09-13

  Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

  提供具有HDAC6调节活性的化合物，以及通过HDAC6介导的治疗疾病、疾病或症状的方法。
• Arylation of α-Chiral Ketones by Palladium-Catalyzed Cross-Coupling Reactions of Tosylhydrazones with Aryl Halides
  作者：José Barluenga、María Escribano、Fernando Aznar、Carlos Valdés

  DOI：10.1002/anie.201003450

  日期：2010.9.10

  Arylation of ketones with preservation of the chirality in configurationally unstable α‐chiral ketones has been achieved by the palladium‐catalyzed cross‐coupling reaction between tosylhydrazones and aryl halides (see scheme; Boc=tert‐butoxycarbonyl, Ts=4‐toluenesulfonyl). The regioselectivity in the β‐hydride elimination step is key for the retention of configuration.

  爸爸是一个罗林酮：在构型上不稳定的α手性酮与手性的保存酮的芳基化已被钯催化交叉偶联甲苯磺酰腙和芳基卤化物之间的反应（参见方案来实现将Boc =叔丁氧羰基中，Ts = 4-甲苯磺酰基）。β-氢化物消除步骤中的区域选择性是保持构型的关键。
• Inhibitors of P2X3
  申请人：Brotherton-Pleiss E. Christine

  公开号：US20070037974A1

  公开（公告）日：2007-02-15

  Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genito-urinary, gastrointestinal, and respiratory disorders: wherein R 1 is —C(═S)CH 3 , pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R 2a and R 2b are independently H, methyl, or ethyl; R 3 is H or methyl; Y is a bond, —(CR 4 R 5 ) n — or —CR 4 ═CR 5 —; wherein R 4 and R 5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R 6 , R 7 and R 8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R 6 and R 7 together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R 1 is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.

  式1的化合物是P2X3的调节剂，用于治疗疼痛和泌尿生殖、胃肠和呼吸系统疾病： 其中 R 1 为—C(═S)CH 3 ，吡啶基，嘧啶基，吡嗪基，噻唑基，呋喃基，呋喃甲酰基，乙酰基或氨基甲酰基；R 2a 和R 2b 独立地为H，甲基或乙基；R 3 为H或甲基；Y为键，—(CR 4 R 5 ) n —或—CR 4 ═CR 5 —；其中R 4 和R 5 各自独立地为H或甲基，n为1或2；X为N或CH；A为苯基，5-成员杂环基或6-成员杂环基；R 6 ，R 7 和R 8 各自独立地为H，卤素，低碳基，环烷基，烷基硫醚，烷基硫醚-低碳基，烷基磺酰基-低碳基，二(低碳基)氨基-低碳基，吗啉基-低碳基，4-甲基哌嗪基-甲基，三氟甲基，吡啶基，四唑基，噻吩基，苯基，联苯基或苄基（其中噻吩基，苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基或低烷硫基取代）或R 6 和R 7 一起形成一个被0-3个取自由低碳基，低烷氧基，氧代基，卤素，噻吩基-低碳基，苯基，苄基（其中苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基，低烷硫基，氨基-低碳基，烷基氨基-低碳基或二(低碳基)氨基-低碳基取代）的5-成员或6-成员碳环或杂环取代环；及其药学上可接受的盐；其中当R 1 为嘧啶-2-基时，X为N，Y为键，A为噁唑-5-基时，所述噁唑-5-基中位置4的碳原子在所述噁唑-5-基中位置2的碳原子被取代的苯基取代时不被丙基取代，且所述噁唑-5-基中位置4的碳原子在位置2被取代的苯基取代时不被苯基取代。
• Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as
  申请人：Pfizer, Inc.

  公开号：US06107329A1

  公开（公告）日：2000-08-22

  Compounds of Formula (1) wherein R.sub.6 is carboxy, (C.sub.1 -C.sub.8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR.sub.8 R.sub.9 or C(O)R.sub.12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

  公式（1）的化合物，其中R6是羧基，（C1-C8）烷氧基羰基，苄氧基羰基，C(O)NR8R9或C(O)R12作为葡萄糖磷酸化酶抑制剂，包含此类抑制剂的药物组合物以及使用此类抑制剂治疗哺乳动物中的糖尿病、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和心肌缺血。
• [EN] PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE TRIAZINE, ET LEUR UTILISATION COMME INHIBITEURS D'AXL
  申请人：PFIZER

  公开号：WO2016097918A1

  公开（公告）日：2016-06-23

  Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  公式(I)的化合物： (I) 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。